State vs. Federal: The Legal Landscape After Oregon and Colorado

“Psilocybin is Schedule I under federal law and legal in Oregon and Colorado. The same legal architecture that produced cannabis's state-federal conflict is now producing psychedelics' state-federal conflict.”

When Oregon's Measure 109 took effect in 2023, psilocybin became simultaneously Schedule I under federal law and regulated-legal under Oregon state law, the same legal architecture governing cannabis since Colorado and Washington's 2012 recreational legalization votes.

The psychedelic state-federal conflict is being managed through prosecutorial discretion: the DEA and DOJ have not challenged Oregon's psilocybin services program or Colorado's Natural Medicine Health Act. Over 100 service centers operate openly under Oregon state law without federal interference.

This arrangement is legally precarious: it depends on continued prosecutorial discretion, which could change with a new administration. The cannabis industry spent years seeking banking access and insurance coverage, complicated by the federal-state conflict. The psychedelic therapy industry will face the same complications unless federal law changes.

Federal psilocybin rescheduling, accompanying FDA approval of synthetic psilocybin, if approved, would resolve the conflict for psilocybin in clinical contexts. It would not resolve the conflict for broader decriminalization provisions in Colorado and Oregon.

The Cato Institute's 2025 analysis argues state-level innovation should proceed regardless of federal action. The cannabis precedent supports this: state legalization preceded federal policy change and drove it. Stevens documented the 1968 federal destruction of psychedelic research; current states are building a record that may prevent a similar destruction.

Sources

• Wikipedia Psilocybin Decriminalization in the United States
• Mindmedicinelaw.com (2026)
• Cato Institute Future of Psychedelic Regulation (2025)